Every cancer patient deserves the right treatment for their individual form of cancer.
New The power of precision, For Every Oncologist, Today
With IndiTreat, 2cureX makes the testing of chemotherapeutic agents on patient-derived microtumors an operational reality.
Read
Latest News
IGNITE update – Eight hospitals have been enrolled in the program
Read more
For over 2 decades, testing cancer treatments on microtumors rather than on the patient has been on the horizon. With IndiTreat®, 2cureX makes microtumor testing an operational reality to serve you and your cancer clinic.
IndiTreat tests determine the sensitivity to different drug regimens for certain types of metastic colorectral cancer. Ask your doctor if it is possible to consider IndiTreat for your cancer.
May 17
IR
Three IndiTreat® posters have been accepted at ESMO-GI 2022
May 12
Regulatory
2cureX AB nominates Dr. Michael Schaefer to the Board of Directors
Swedish
2cureX AB nominerar Dr. Michael Schaefer till styrelsen
May 11
Get notified on mail, when news or press releases are posted on our website